1. Home
  2. GBIO vs WYY Comparison

GBIO vs WYY Comparison

Compare GBIO & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • WYY
  • Stock Information
  • Founded
  • GBIO 2016
  • WYY 1991
  • Country
  • GBIO United States
  • WYY United States
  • Employees
  • GBIO N/A
  • WYY N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • WYY EDP Services
  • Sector
  • GBIO Health Care
  • WYY Technology
  • Exchange
  • GBIO Nasdaq
  • WYY Nasdaq
  • Market Cap
  • GBIO 29.5M
  • WYY 33.6M
  • IPO Year
  • GBIO 2020
  • WYY 1998
  • Fundamental
  • Price
  • GBIO $4.51
  • WYY $2.96
  • Analyst Decision
  • GBIO Strong Buy
  • WYY Strong Buy
  • Analyst Count
  • GBIO 4
  • WYY 1
  • Target Price
  • GBIO $73.33
  • WYY $7.00
  • AVG Volume (30 Days)
  • GBIO 206.6K
  • WYY 58.6K
  • Earning Date
  • GBIO 08-06-2025
  • WYY 08-14-2025
  • Dividend Yield
  • GBIO N/A
  • WYY N/A
  • EPS Growth
  • GBIO N/A
  • WYY N/A
  • EPS
  • GBIO N/A
  • WYY N/A
  • Revenue
  • GBIO $24,556,000.00
  • WYY $142,582,209.00
  • Revenue This Year
  • GBIO N/A
  • WYY $9.05
  • Revenue Next Year
  • GBIO N/A
  • WYY $12.24
  • P/E Ratio
  • GBIO N/A
  • WYY N/A
  • Revenue Growth
  • GBIO 146.47
  • WYY 24.03
  • 52 Week Low
  • GBIO $3.00
  • WYY $2.19
  • 52 Week High
  • GBIO $34.35
  • WYY $6.25
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 54.72
  • WYY 41.39
  • Support Level
  • GBIO $4.05
  • WYY $2.99
  • Resistance Level
  • GBIO $5.10
  • WYY $3.23
  • Average True Range (ATR)
  • GBIO 0.63
  • WYY 0.19
  • MACD
  • GBIO 0.02
  • WYY -0.01
  • Stochastic Oscillator
  • GBIO 35.65
  • WYY 27.59

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: